# Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

> **NCT03300479** · PHASE4 · WITHDRAWN · sponsor: **University of Zurich**

## Conditions studied

- Nontraumatic Intracerebral Hemorrhage, Multiple Localized

## Interventions

- **DRUG:** Clevidipine
- **DRUG:** Urapidil

## Key facts

- **NCT ID:** NCT03300479
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06-15
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-05-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patient enrolled. No study conduct due to lack of human resources.
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300479, "Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03300479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*